|
1
|
Nahta R and O'Regan RM: Therapeutic
implications of estrogen receptor signaling in HER2-positive breast
cancers. Breast Cancer Res Treat. 135:39–48. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Benz CC, Scott GK, Sarup JC, Johnson RM,
Tripathy D, Coronado E, Shepard HM and Osborne CK:
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7
cells trans-fected with HER2/neu. Breast Cancer Res Treat.
24:85–95. 1992. View Article : Google Scholar
|
|
3
|
Bhargava R, Dabbs DJ, Beriwal S, Yildiz
IA, Badve P, Soran A, Johnson RR, Brufsky AM, Lembersky BC, McGuire
KP, et al: Semiquantitative hormone receptor level influences
response to trastuzumab-containing neoadjuvant chemotherapy in
HER2-positive breast cancer. Mod Pathol. 24:367–374. 2011.
View Article : Google Scholar
|
|
4
|
Vici P, Pizzuti L, Sperduti I, Frassoldati
A, Natoli C, Gamucci T, Tomao S, Michelotti A, Moscetti L, Gori S,
et al: 'Triple positive' early breast cancer: An observational
multicenter retrospective analysis of outcome. Oncotarget.
7:17932–17944. 2016.PubMed/NCBI
|
|
5
|
Kaufman B, Mackey JR, Clemens MR, Bapsy
PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Feyereislova
A, et al: Trastuzumab plus anastrozole versus anastrozole alone for
the treatment of postmenopausal women with human epidermal growth
factor receptor 2-positive, hormone receptor-positive metastatic
breast cancer: Results from the randomized phase III TAnDEM study.
J Clin Oncol. 27:5529–5537. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Johnston S, Pippen J Jr, Pivot X,
Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A,
Kennedy MJ, et al: Lapatinib combined with letrozole versus
letrozole and placebo as first-line therapy for postmenopausal
hormone receptor-positive metastatic breast cancer. J Clin Oncol.
27:5538–5546. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee AV, Jackson JG, Gooch JL, Hilsenbeck
SG, Coronado-Heinsohn E, Osborne CK and Yee D: Enhancement of
insulin-like growth factor signaling in human breast cancer:
Estrogen regulation of insulin receptor substrate-1 expression in
vitro and in vivo. Mol Endocrinol. 13:787–796. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Molloy CA, May FEB and Westley BR: Insulin
receptor substrate-1 expression is regulated by estrogen in the
MCF-7 human breast cancer cell line. J Biol Chem. 275:12565–12571.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hamelers IH and Steenbergh PH:
Interactions between estrogen and insulin-like growth factor
signaling pathways in human breast tumor cells. Endocr Relat
Cancer. 10:331–345. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Casa AJ, Potter AS, Malik S, Lazard Z,
Kuiatse I, Kim HT, Tsimelzon A, Creighton CJ, Hilsenbeck SG, Brown
PH, et al: Estrogen and insulin-like growth factor-I (IGF-I)
independently down-regulate critical repressors of breast cancer
growth. Breast Cancer Res Treat. 132:61–73. 2012. View Article : Google Scholar
|
|
11
|
Ye JJ, Liang SJ, Guo N, Li SL, Wu AM,
Giannini S, Sachdev D, Yee D, Brünner N, Ikle D, et al: Combined
effects of tamoxifen and a chimeric humanized single chain antibody
against the type I IGF receptor on breast tumor growth in vivo.
Horm Metab Res. 35:836–842. 2003. View Article : Google Scholar
|
|
12
|
Lisztwan J, Pornon A, Chen B, Chen S and
Evans DB: The aromatase inhibitor letrozole and inhibitors of
insulin-like growth factor I receptor synergistically induce
apoptosis in in vitro models of estrogen-dependent breast cancer.
Breast Cancer Res. 10:R562008. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chakraborty AK, Welsh A and Digiovanna MP:
Co-targeting the insulin-like growth factor I receptor enhances
growth-inhibitory and pro-apoptotic effects of anti-estrogens in
human breast cancer cell lines. Breast Cancer Res Treat.
120:327–335. 2010. View Article : Google Scholar
|
|
14
|
Hou X, Huang F, Macedo LF, Harrington SC,
Reeves KA, Greer A, Finckenstein FG, Brodie A, Gottardis MM,
Carboni JM, et al: Dual IGF-1R/InsR inhibitor BMS-754807 synergizes
with hormonal agents in treatment of estrogen-dependent breast
cancer. Cancer Res. 71:7597–7607. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Robertson JFR, Ferrero JM, Bourgeois H,
Kennecke H, de Boer RH, Jacot W, McGreivy J, Suzuki S, Zhu M,
McCaffery I, et al: Ganitumab with either exemestane or fulvestrant
for postmenopausal women with advanced, hormone-receptor-positive
breast cancer: A randomised, controlled, double-blind, phase 2
trial. Lancet Oncol. 14:228–235. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lu Y, Zi X, Zhao Y, Mascarenhas D and
Pollak M: Insulin-like growth factor-I receptor signaling and
resistance to trastuzumab (Herceptin). J Natl Cancer Inst.
93:1852–1857. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nahta R, Yuan LXH, Zhang B, Kobayashi R
and Esteva FJ: Insulin-like growth factor-I receptor/human
epidermal growth factor receptor 2 heterodimerization contributes
to trastuzumab resistance of breast cancer cells. Cancer Res.
65:11118–11128. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hartog H, Van Der Graaf WTA, Boezen HM and
Wesseling J: Treatment of breast cancer cells by IGF1R tyrosine
kinase inhibitor combined with conventional systemic drugs.
Anticancer Res. 32:1309–1318. 2012.PubMed/NCBI
|
|
19
|
Browne BC, Eustace AJ, Kennedy S, O'Brien
NA, Pedersen K, McDermott MSJ, Larkin A, Ballot J, Mahgoub T,
Sclafani F, et al: Evaluation of IGF1R and phosphorylated IGF1R as
targets in HER2-positive breast cancer cell lines and tumours.
Breast Cancer Res Treat. 136:717–727. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Haluska P, Bernath AM, Ballman KV, Dueck
AC, Linden HM, Goetz MP, Northfelt DW, Hou X, Tenner KS,
Tienchaiananda P, et al: Randomized phase II trial of capecitabine
and lapatinib with or without cixutumumab in patients with HER2
breast cancer previously treated with trastuzumab and an
anthracycline and/or a taxane: NCCTG N0733 (Alliance). J Clin
Oncol. 32(Suppl 5): 6322014.
|
|
21
|
Konecny GE, Pegram MD, Venkatesan N, Finn
R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, et
al: Activity of the dual kinase inhibitor lapatinib (GW572016)
against HER-2-overexpressing and trastuzumab-treated breast cancer
cells. Cancer Res. 66:1630–1639. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Madden SF, Clarke C, Gaule P, Aherne ST,
O'Donovan N, Clynes M, Crown J and Gallagher WM: BreastMark: An
integrated approach to mining publicly available transcriptomic
datasets relating to breast cancer outcome. Breast Cancer Res.
15:R522013. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sorlie T, Tibshirani R, Parker J, Hastie
T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et
al: Repeated observation of breast tumor subtypes in independent
gene expression data sets. Proc Natl Acad Sci USA. 100:8418–8423.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dupont J and Le Roith D: Insulin-like
growth factor 1 and oestradiol promote cell proliferation of MCF-7
breast cancer cells: New insights into their synergistic effects.
Mol Pathol. 54:149–154. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
García-Echeverría C, Pearson MA, Marti A,
Meyer T, Mestan J, Zimmermann J, Gao J, Brueggen J, Capraro HG,
Cozens R, et al: In vivo antitumor activity of NVP-AEW541-A novel,
potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell.
5:231–239. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wittman M, Carboni J, Attar R,
Balasubramanian B, Balimane P, Brassil P, Beaulieu F, Chang C,
Clarke W, Dell J, et al: Discovery of a
(1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of
insulin-like growth factor I receptor kinase with in vivo antitumor
activity. J Med Chem. 48:5639–5643. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ferguson RD, Gallagher EJ, Cohen D,
Tobin-Hess A, Alikhani N, Novosyadlyy R, Haddad N, Yakar S and
LeRoith D: Hyperinsulinemia promotes metastasis to the lung in a
mouse model of Her2-mediated breast cancer. Endocr Relat Cancer.
20:391–401. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mukohara T, Shimada H, Ogasawara N,
Wanikawa R, Shimomura M, Nakatsura T, Ishii G, Park JO, Jänne PA,
Saijo N, et al: Sensitivity of breast cancer cell lines to the
novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor
NVP-AEW541 is dependent on the level of IRS-1 expression. Cancer
Lett. 282:14–24. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bundred N, Cameron D, Armstrong A, Brunt
A, Cramer A, Dodwell D, Evans A, Hanby A, Hartup S, Hong A, et al:
Effects of perioperative lapatinib and trastuzumab, alone and in
combination, in early HER2+ breast cancer - the UK
EPHOS-B trial (CRUK/08/002). Eur J Cancer. 57(Suppl 2):
LBA62016.
|
|
30
|
Yee D: Insulin-like growth factor receptor
inhibitors: Baby or the bathwater? J Natl Cancer Inst. 104:975–981.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Crudden C, Girnita A and Girnita L:
Targeting the IGF-1R: The tale of the tortoise and the hare. Front
Endocrinol (Lausanne). 6:642015.
|
|
32
|
Javle MM, Shroff RT, Varadhachary GR,
Wolff RA, Fogelman DR, Bhosale P, Wang X, Kar SP, Overman MJ,
Sathyanarayanan S, et al: Tumor IGF-1 expression as a predictive
biomarker for IGF1R-directed therapy in advanced pancreatic cancer
(APC). J Clin Oncol. 30:40542012.
|
|
33
|
McCaffery I, Tudor Y, Deng H, Tang R,
Suzuki S, Badola S, Kindler HL, Fuchs CS, Loh E, Patterson SD, et
al: Putative predictive biomarkers of survival in patients with
metastatic pancreatic adenocarcinoma treated with gemcitabine and
ganitumab, an IGF1R inhibitor. Clin Cancer Res. 19:4282–4289. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gao J, Chesebrough JW, Cartlidge SA,
Ricketts SA, Incognito L, Veldman-Jones M, Blakey DC, Tabrizi M,
Jallal B, Trail PA, et al: Dual IGF-I/II-neutralizing antibody
MEDI-573 potently inhibits IGF signaling and tumor growth. Cancer
Res. 71:1029–1040. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Friedbichler K, Hofmann MH, Kroez M,
Ostermann E, Lamche HR, Koessl C, Borges E, Pollak MN, Adolf G and
Adam PJ: Pharmacodynamic and antineoplastic activity of BI 836845,
a fully human IGF ligand-neutralizing antibody, and mechanistic
rationale for combination with rapamycin. Mol Cancer Ther.
13:399–409. 2014. View Article : Google Scholar
|
